← SOPHiA GENETICS SA (SOPH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
SOPHiA GENETICS SA (SOPH)
Services-Computer Processing & Data Preparation · market cap $551M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
12
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
SOPHiA GENETICS SA (SOPH) is a Swiss-founded data-driven medicine software company serving hospitals, laboratories, and biopharma institutions through genomic, radiomic, and multimodal analysis platforms. However, the FACTS provided include a pipeline of ophthalmic drug candidates — including Phase 3 assets in cataract, glaucoma, dry eye, myopia, and diabetic macular edema — that are inconsistent with the company's described software/data services business, suggesting a data mismatch in the sourced pipeline information. The company trades at approximately $5.44 with a market cap of ~$448M, analyst price targets ranging $7–$9, and a next catalyst of Q2 2026 earnings on August 4.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Sodium Hyaluronate Ophthalmic 0.4% BID | Phase 2 | Dry Eye |
| Difluprednate 0.05% | Phase 3 | Cataract |
| Lucentis® | Phase 3 | Diabetic Macular Edema |
| Alleance® | Phase 3 | Myopia |
| Moxifloxacin / Dexamethasone Ophthalmic Solution | Phase 3 | Cataract Extraction |
| PRO-122 | Phase 3 | Primary Open Angle Glaucoma |
| Nanodrop® | Phase 2 | Dry Eye |
| PRO-155 | Phase 2 | Cataract |
| dorzolamide-timolol-brimonidine | Phase 2 | Primary Open Angle Glaucoma |
| PRO-148 | Phase 3 | Dry Eye |
| PRO-148 Ophthalmic Solution | Phase 2 | Dry Eye Syndrome |
| PRO-157 | Phase 2 | Bacterial Conjunctivitis |
Price & technical context
3-month
+50.1%
6-month
+57.8%
12-month
+68.7%
52-wk range
$3.89–$8.92
vs 50-day MA
+5.1%
vs 200-day MA
+41.3%
Realized vol
62.7%
Max drawdown
-45.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SOPH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.